Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Scientists have discovered a new anti-cancer drug-EBV protein inhibitor

Page View:

Epstein-Barr virus (EBV) is a herpes virus that is pathogenic to humans. It has been found to be associated with nasopharyngeal cancer, some gastric cancer, laryngeal cancer, and Hodgkin’s lymphoma. Although the proportion of EB virus directly causing cancer is very low, because of the high proportion of human infections, the eradication of cancer caused by EB virus has been listed as a challenge by scientists. Recently, a scientist described a class of Epstein-Barr nuclear antigen 1 (EBNA1) inhibitors of the EBV protein, studied the therapeutic effects of these inhibitors on EBV-related mouse tumor models, and found that the tumor growth of all mice Significantly slowed down and combined with radiotherapy or chemotherapy can further enhance the therapeutic effect.

The most common disease caused by EB virus infection in humans is infectious mononucleosis. Because it is mainly transmitted through saliva, it has a higher incidence among young people. It is also called “kissing disease,” but most infections are asymptomatic. According to statistics in the United States, the EB virus infection rate of 5-year-old children has reached about 50%, and the infection rate at the age of 40 is as high as 90%. Once stimulated by genetics, living habits (dietary structure), and other carcinogenic factors, some virus carriers will relapse and even cause cancer.

Some researchers have made a mouse whose B lymphocytes can express the Epstein-Barr virus membrane protein LMP1, which can be used as a mouse tumor model of lymphoma. This mouse tumor model expressing LMP1 protein can be used for EB virus-induced immune surveillance and lymphoma research and can verify whether the new treatment method is effective. Medicilon provides a variety of effective animal models according to customer needs to test the effectiveness of drugs. Experimental animals include non-human primates, dogs, mice, rats, rabbits, guinea pigs, nude mice, and other species. At present, several effective animal tumor models have been established, and they have been verified by multiple parties and tested in long-term practice.

Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.

Tumor Animal Model Medicilon Has Established:

 ❖ PDX Models

 ❖ Transgenic Models

 ❖ Humanized Mouse Models

 ❖ Syngeneic Mouse Models

 ❖ Orthotopic Cancer Models

 ❖ Xenograft Models

Studies have found that the most fundamental reason for the cancelation of a small number of patients infected with the Epstein-Barr virus is that the immune system lacks an effective attack on the Epstein-Barr virus. As a result, these viruses can reproduce unscrupulously in cells, secrete many proteins, and send out wrong messages, making the original The uncontrolled replication of normal cells produces cancer. EBNA1 is a viral determinant antigen that appears in the early stage of EB virus-infected cells. It plays a vital role in cell transformation and maintenance, and its virus will continue to exist in the final stage of the replication cycle. It has been reported that EBNA1 is used to detect nasopharyngeal carcinoma. The sensitivity and specificity of (NPC) are as high as 90%, and EBNA1 is considered an excellent indicator for detecting nasopharyngeal carcinoma.

The corresponding author of the study, Professor Paul M. Lieberman, head of the Gene Expression and Regulation Research Group of the Weststar Institute, said that the characteristics of EBNA1 and the unique structure of this protein make it an attractive therapeutic target. Based on the 3D design of this protein, Lieberman and colleagues created a class of small molecule inhibitors that can inhibit its binding protein and verified it on EBV-infected NPC cells.

Researchers conducted studies on EBV-related mouse tumor models derived from transplanted or patient-derived tumor cells. They found that these inhibitors can significantly slow down the growth of tumors in all mice, compared with radiotherapy. The combined use of chemotherapy can further enhance the therapeutic effect. According to Dr. Troy E. Messick, the first author of the study, co-corresponding author, and senior scientist in Lieberman’s laboratory, it took nearly a decade for this study from a concept to now find a clinical drug candidate. They are delighted with the efficacy of these inhibitors in a series of preclinical studies and look forward to further in-depth studies.

EBNA1 inhibitors have significant effects on the gene expression of EBV and host cells, related to the reduction of EBV DNA replication and the inhibition of EBV-derived tumor-promoting signals. Notably, the experimental results show that the treatment effect is significant, and there is no sign of drug resistance after long-term use.

EBV is a human herpes virus with a complex genome closely related to many human diseases. The cancers caused by EBV are mainly lymphoma, laryngeal cancer, nasopharyngeal cancer, and gastric cancer. Scientists aim to fundamentally solve the carcinogenic problem of EBV infection through various methods, such as vaccine prevention, immunological diagnosis, and treatment. Scientists from the United States discovered EBNA1 inhibitors and studied them in mouse tumor models. The curative effect is remarkable. It can be said that it is a significant discovery in the development of EBV drugs and has paramount significance.

Relevant newsRelevant news